For example, the CITYSCAPE Fase II trial showed that tiragolumab (anti-TIGIT) plus atezolizumab (anti-PD-L1) improved response rates and survival outcomes in patients with lung cancer [28]. This evidence concerns the gene CD274 and lung carcinoma.